'Viral loads' presentation slideshows

Pediatric HIV Treatment Guidelines Update

910 views • 69 slides

1.21k views • 60 slides

Lecture 20 Evolution and vaccines

Lecture 20 Evolution and vaccines. Today:. A bit more about drug therapy Different sorts of vaccines Could vaccines increase virulence? Or decrease it? Why HIV is hard to vaccinate against. Antiretroviral therapy and HIV/AIDS. There are 3 phases of HIV disease:.

668 views • 51 slides

National TA Call: Improving Patient Retention May 13, 2010 Facilitator: Nanette Brey Magnani, Ed.D., NQC and HIVQUAL Qua

National TA Call: Improving Patient Retention May 13, 2010 Facilitator: Nanette Brey Magnani, Ed.D., NQC and HIVQUAL Quality Consultant. Learning Objectives. Review evidence for working on retention Discuss several retention performance measures for your HIV program

631 views • 44 slides

IS HOUSING THE BEST MEDICINE?

IS HOUSING THE BEST MEDICINE?. The Role of Housing in Chronic Disease Management Keith Hambly and Floyd Visser Co-Chairs National HIV and Housing Collaborative. NATIONAL HIV AND HOUSING COLLABORATIVE.

538 views • 44 slides

A Journey Through AIDS

671 views • 43 slides

Dear Sister,

Dear Sister, I have received your letter of February 29 in which you express concern and question the teaching of evolution at BYU-Idaho. I thank you for expressing your feelings, and I will try to relate to you why I feel that the teaching of evolution is important here.

683 views • 40 slides

Department of Health and Human Services Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral H

Department of Health and Human Services Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Integrating HIV Prevention into Care and Treatment: Four Key Strategies Pamela Bachanas, PhD Atlanta, GA September 2007.

592 views • 31 slides

Laboratory Monitoring for HIV+ Patients: What You Need to Know

HIVI. HIV Initiative of Kaiser Permanente and Care Management Institute. Michael Horberg, MD MAS FACP FIDSA Executive Director Research, Mid-Atlantic Permanente Research Institute Director HIV/AIDS, Kaiser Permanente Vice-Chair, HIV Medicine Association. Laboratory Monitoring for HIV+ Patients:

389 views • 29 slides

SURGERY IN THE HIV POSITIVE PATIENT

SURGERY IN THE HIV POSITIVE PATIENT Dr A Mouton HIV infection continues to be major cause of morbidity and mortality WHO estimate 40 million people world wide infected AIDS now fourth largest cause of death worldwide Sub-Sahara Africa ? most common cause of death

1.46k views • 22 slides

Professor Vishanthie Sewpaul (PhD) University of KwaZulu Natal South Africa

312 views • 16 slides

HIV, CD4, and More

197 views • 10 slides

Modeling the population dynamics of HIV/AIDS

Modeling the population dynamics of HIV/AIDS. Brandy L. Rapatski James A. Yorke Frederick Suppe. Primary Goal. To determine how infectiousness of HIV varies as an untreated infected gay man progresses through 3 stages of the disease .

195 views • 10 slides

Authors: Nakanjako D , Kiragga A, Yiannoutsos C,

Suboptimal immune response among adults on first-line antiretroviral therapy within the IeDEA East Africa cohort. Authors: Nakanjako D , Kiragga A, Yiannoutsos C, Kambugu A, Easterbrook P, on behalf of IeDEA - EA. Definitions of suboptimal CD4 recovery.

131 views • 7 slides

VIRTUAL MEDZONE

VIRTUAL MEDZONE. Your Resource for HIV Related Innovative Medical Communication. HIV CASE PRESENTATIONS. David Fletcher MD FRCPC. CASE 1 Follow-up. Proviral DNA tropism testing revealed non-R5 virus hence Maraviroc was not a viable option . CASE 1 Follow-up.

128 views • 5 slides

Top Research Priorities of STDWG

Top Research Priorities of STDWG. Impact of a RCT of HSV-2 suppression in prevention of HIV infection (Discretionary funds--039 and R01)

120 views • 5 slides

Engagement in HIV care: changes with time, migration, and death

Engagement in HIV care: changes with time, migration, and death. Background. Engagement estimates typically cross-sectional or at fixed interval after HIV diagnosis. Objectives. Engagement in care 18 months after HIV diagnosis. Describe the engagement cascade over time

103 views • 3 slides

Poster # 873 *Sharon Nachman SUNY Stony Brook Stony Brook, NY sharon.nachman@stonybrook

CROI 2010 San Francisco, CA. . . Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth . Poster # 873 *Sharon Nachman SUNY Stony Brook Stony Brook, NY

216 views • 1 slides

Acceptable adherence and treatment outcomes among refugees and host community on HAART in an urban refugee setting in Ku

Acceptable adherence and treatment outcomes among refugees and host community on HAART in an urban refugee setting in Kuala Lumpur, Malaysia THPDD0103. Poor treatment outcomes among both refugees and host community accessing HAART from Kakuma refugee camp, Northwestern Kenya THPDD0102.

165 views • 0 slides

Individual level Early warning indicators for Virological failure (independent of adherence)

186 views • 0 slides